Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review

Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR‐sensitive and EGFR T790M‐resistant mutations. Patients with pre‐treatment EGFR T790M mutations (de novo EGFR T790M) respond poorly to existing EGFR‐TKIs...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Respirol Case Rep
Hoofdauteurs: Sumi, Toshiyuki, Kamada, Koki, Shijubou, Naoki, Yamada, Yuichi, Nakata, Hisashi, Mori, Yuji, Chiba, Hirofumi
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Ltd 2021
Onderwerpen:
Case Reports
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094050/
https://ncbi.nlm.nih.gov/pubmed/33976888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.759
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items